文献速递免疫规划

含单磷酸酰脂质A和QS-21的脂质体作为可溶性环子孢子蛋白疟疾疫苗FMP013的有效佐剂

Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
PubMed 文献 · Vaccine · 2017-06-07

研究在C57BL/6小鼠中比较FMP013抗原搭配ALF系列新型佐剂与Montanide ISA 720的免疫原性和攻击保护效果。ALFQ(含QS-21)诱导的抗体滴度、IgG2c、保护效果及B细胞和T细胞应答均优于其他佐剂,结果用于非人灵长类研究和法规毒理研究以推进控制性人类疟疾感染试验。

要点

  • ALF和ALFA诱导的抗体滴度与保护效果与Montanide相当。
  • ALFQ诱导的抗体滴度更高、第三剂后加强更好、IgG2c更高、保护更强。
  • FMP013+ALFQ增强脾生发中心来源活化B细胞和抗体分泌细胞并诱导TH1偏向细胞因子谱。

核心结论

  • 可溶性CSP与含QS-21佐剂ALFQ配伍时可诱导强效且无菌的保护性免疫应答。

研究设计与样本

  • 在C57BL/6小鼠中评价FMP013抗原搭配ALF、ALFA、ALFQ及对照佐剂Montanide ISA 720的免疫原性和攻击数据。

主要发现

  • ALF和ALFA诱导的抗体滴度及对转基因寄生虫攻击的保护效果与Montanide相当。
  • ALFQ优于其他三种佐剂,诱导更高抗体滴度、第三剂后加强更好、血清IgG2c滴度更高且保护增强。
  • FMP013+ALFQ较Montanide增加脾生发中心来源活化B细胞和抗体分泌细胞数量。
  • FMP013+ALFQ诱导抗原特异性IFN-γ ELISPOT活性、CD4+ T细胞和TH1偏向细胞因子谱。

临床怎么用

  • 小鼠免疫原性比较数据已用作正在进行的非人灵长类研究和法规毒理研究的推进标准,以准备控制性人类疟疾感染(CHMI)试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Malaria caused by Plasmodium falciparum continues to threaten millions of people living in the tropical parts of the world. A vaccine that confers sterile and life-long protection remains elusive despite more than 30years of effort and resources invested in solving this problem. Antibodies to a malaria vaccine candidate circumsporozoite protein (CSP) can block invasion and can protect humans against malaria. We have manufactured the Falciparum Malaria Protein-013 (FMP013) vaccine based on the nearly full-length P. falciparum CSP 3D7 strain sequence. We report here immunogenicity and challenge data on FMP013 antigen in C57BL/6 mice formulated with two novel adjuvants of the Army Liposome Formulation (ALF) series and a commercially available adjuvant Montanide ISA 720 (Montanide) as a control. ALF is a liposomal adjuvant containing a synthetic monophosphoryl lipid A (3D-PHAD®). In our study, FMP013 was adjuvanted with ALF alone, ALF containing aluminum hydroxide (ALFA) or ALF containing QS-21 (ALFQ). Adjuvants ALF and ALFA induced similar antibody titers and protection against transgenic parasite challenge that were comparable to Montanide. ALFQ was superior to the other three adjuvants as it induced higher antibody titers with improved boosting after the third immunization, higher serum IgG2c titers, and enhanced protection. FMP013+ALFQ also augmented the numbers of splenic germinal center-derived activated B-cells and antibody secreting cells compared to Montanide. Further, FMP013+ALFQ induced antigen-specific IFN-γ ELISPOT activity, CD4+ T-cells and a TH1-biased cytokine profile. These results demonstrate that soluble CSP can induce a potent and sterile protective immune response when formulated with the QS-21 containing adjuvant ALFQ. Comparative mouse immunogenicity data presented here were used as the progression criteria for an ongoing non-human primate study and a regulatory toxicology study in preparation for a controlled human malaria infection (CHMI) trial.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Genito CJ, Beck Z, Phares TW, et al. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013. Vaccine. 2017. PMID: 28596090. doi:10.1016/j.vaccine.2017.05.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。